汇宇制药：注射用HY05350 I期临床试验完成首例受试者给药

Core Points - The company Huayu Pharmaceutical (688553) announced that its wholly-owned subsidiary Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd. has developed a first-class innovative biological drug, injectable HY05350, which is currently undergoing Phase I clinical trials for the treatment of advanced solid tumors [1] Group 1 - The injectable drug HY05350 is identified by the project research code "HY-0005" [1] - The first patient has successfully received the drug in the clinical trial [1]